IFF to Sell Food Ingredients Unit to CVC

IFF has agreed to transfer its Food Ingredients business to CVC Capital Partners. The provided material for this article does not include transaction economics, timing or closing conditions. The Food Ingredients business was established as a separate reportable segment after the Q1 2025 reorganization that split the former Nourish reporting into Taste and Food Ingredients. On a portfolio level, the sale represents a material carve‑out: Food Ingredients accounted for roughly three tenths of IFF’s 2025 net sales and about one fifth of adjusted operating EBITDA. The transfer of that revenue and earnings base to a private‑equity owner will change IFF’s public reporting mix and the scale of its remaining segments (Taste, Scent, Health & Biosciences).

Key 2025 segment figures illustrate the scale of the business being sold: Food Ingredients—$3,278 million net sales (30.1%) and $423 million adjusted operating EBITDA (20.3%). Removing Food Ingredients from IFF’s consolidated results would leave the combined Taste, Scent and Health & Biosciences segments with $7,243 million in net sales (about 66.5% of 2025 consolidated sales) and approximately $1,587 million of adjusted operating EBITDA (about 76.1% of consolidated adjusted operating EBITDA). Investors should note these are 2025 baseline metrics. Any analysis of post‑transaction leverage, margin profile or capital allocation will depend on transaction proceeds, working capital and any retained liabilities or transitional arrangements — none of which are specified in the supplied material for this article.

The divestiture is consistent with the portfolio optimization trend visible in IFF’s recent filings (for example, the May 2025 Pharma Solutions divestiture). Selling a large Food Ingredients unit concentrates IFF’s exposure toward Taste, Scent and Health & Biosciences, where R&D and customer‑facing innovation are emphasized. IFF’s filings highlight an intensely competitive landscape without a clearly sustainable economic moat: large global peers (Givaudan, Symrise, DSM‑Firmenich) and regional players compete on innovation, customer intimacy and supply‑chain execution. The company also faces legal/regulatory and environmental compliance risks, raw‑material price volatility (botanicals, commodity crops), and previously disclosed accounting revisions in its 2025 10‑K. Additionally, historical debt dynamics (including $2.913 billion of principal payments noted for 2025 and the June 2026 $1 billion term loan entry) form part of the financial backdrop for any material corporate transaction.